A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PopPK / population pharmacokinetic

[Related PubMed/MEDLINE]
Total Number of Papers: 284
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PopPK  (>> Co-occurring Abbreviation)
Long Form:   population pharmacokinetic
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy. ---
2022 A Population Pharmacokinetic Model of Whole-Blood and Intracellular Tacrolimus in Kidney Transplant Recipients. DeltaOFV, NONMEM
2022 Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients. BIS, NONMEM
2022 Clinical Pharmacology and Utility of Contezolid in Chinese Patients with Complicated Skin and Soft-Tissue Infections. AEs, cSSTIs, NONMEM, PK/PD
2022 Combining Therapeutic Drug Monitoring and Pharmacokinetic Modelling Deconvolutes Physiological and Environmental Sources of Variability in Clozapine Exposure. PBPK, TDM
2022 Evaluation and Application of Population Pharmacokinetic Models for Identifying Delayed Methotrexate Elimination in Patients With Primary Central Nervous System Lymphoma. MTX
2022 Factors influencing methotrexate and methotrexate polyglutamate in patients with rheumatoid arthritis: a systematic review of population pharmacokinetics. MTX
2022 Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation. NLME, OFV
2022 Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease. PBPK, PK, VTE
10  2022 Model-informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma. Hb, PK, SCD
11  2022 Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma. aRCC, irAEs, MCC, TEAEs, UC
12  2022 Model-informed precision dosing of vancomycin via continuous infusion: a clinical fit-for-purpose evaluation of published PK models. MAA, MSA
13  2022 Novel extended IVIVC combined with DoE to predict pharmacokinetics from formulation compositions. DoE, IVIVC, SR
14  2022 Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms. NLME, PKs
15  2022 Population Pharmacokinetic Evaluation with External Validation of Tacrolimus in Chinese Primary Nephrotic Syndrome Patients. PNS
16  2022 Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease. BZD
17  2022 Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis. LSS, TB, TDM
18  2022 Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation. DOAC
19  2022 Population pharmacokinetics and Bayesian estimation of mycophenolate mofetil in patients with autoimmune hepatitis. AIH, MAP-BEs, MMF
20  2022 Population pharmacokinetics and exposure-response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours. E-R, ORR, PK
21  2022 Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors. PK
22  2022 Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation. allo-HSCT, CL, TBW, Vd
23  2022 Population pharmacokinetics of doxorubicin: A systematic review. DOX
24  2022 Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women. CGM, GAHT, PK, TFV, TGW
25  2022 Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients. VPA
26  2022 Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic Pseudomonas aeruginosa Lung Infection Based on Preclinical Population Pharmacokinetic Modeling. CL, ELF, MIC, PTA, TOB
27  2022 R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverrini. BA, PZQ
28  2022 Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing. TDD, TDM
29  2022 Using Electronic Health Records for Personalized Dosing of Intravenous Vancomycin in Critically Ill Neonates: Model and Web-Based Interface Development Study. EHRs, NICU, PMA, PTA, SCr
30  2022 Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. HMA, LDAC
31  2021 A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure. PK
32  2021 A single Bayesian estimator for iohexol clearance estimation in ICU, liver failure and renal transplant patients. GFR, LSS, MPE, Vd
33  2021 A systematic review of population pharmacokinetic analyses of polyclonal immunoglobulin G therapy. CL, IgG, NLME, PID
34  2021 Ampicillin Pharmacokinetics During First Week of Life in Preterm and Term Neonates. CL, NCA, PK, Vd
35  2021 An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection. AOM 400
36  2021 Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation. E-R, IA
37  2021 Atorvastatin population pharmacokinetics in a real-life setting: Influence of genetic polymorphisms and association with clinical response. PK, SNP
38  2021 Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis. cAUC, HCT, IMD
39  2021 Can Published Population Pharmacokinetic Models of Busulfan Be Used for Individualized Dosing in Chinese Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation? An External Evaluation. HSCT
40  2021 Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague. PBPK
41  2021 Concordance of Exposure Changes Because of Renal Impairment Between Results of Dedicated Renal Impairment Studies and Population Pharmacokinetic Predictions. AUC, GMR, NMEs, RI
42  2021 Cytochrome P450 2D6 genotype-phenotype characterization through population pharmacokinetic modeling of tedatioxetine. ---
43  2021 Effects of food on the pharmacokinetics of ensartinib in healthy Chinese subjects. ---
44  2021 Establishment of a population pharmacokinetics model of vancomycin in 94 infants with septicemia and its application in individualized therapy. NONMEM, NPDE
45  2021 Estimation of Ontogeny Functions for Renal Transporters Using a Combined Population Pharmacokinetic and Physiology-Based Pharmacokinetic Approach: Application to OAT1,3. CLR, PBPK
46  2021 Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy. AIC, LTG, WWE
47  2021 Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach. ---
48  2021 Evaluation of amoxicillin, metronidazole and gentamicin dosage regimens for use in antibiotic prophylaxis in colorectal surgery. SSIs
49  2021 Evaluation of the estimation and classification performance of NONMEM when applying mixture model for drug clearance. CL, DI, LRT
50  2021 External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia. CML
51  2021 External evaluation of published population pharmacokinetic models of polymyxin B. NPDE
52  2021 Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis. BW, CSCC
53  2021 Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales. LMICs
54  2021 Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach. PEG, PEG-ASNase
55  2021 Location matters: Overlooked ethnic-geographic effect in China and Austria on propofol/cisatracurium sex differences among a population pharmacokinetic/pharmacodynamic (PopPK/PD) covariate analysis in men, women, and one transgender subject. BIS, Cp, LOBR, MMG
56  2021 Model-Informed Therapeutic Drug Monitoring of Meropenem in Critically Ill Patients: Improvement of the Predictive Ability of Literature Models with the PRIOR Approach. TDM
57  2021 Pharmacokinetic Modeling and Predictive Performance: Practical Considerations for Therapeutic Monoclonal Antibodies. AUC, mAbs
58  2021 Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients. ANC, MTT, PK, PK/PD
59  2021 Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. BLyS, pcVPC, RA, SLE, TMDD
60  2021 Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies). DRV
61  2021 Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler® Device in Patients with Asthma. COPD, GLY, IND, MF
62  2021 Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC. AUC, PK, TDM
63  2021 Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions. PBPK, VTE
64  2021 Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies. CSCC, PD-1, PK
65  2021 Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP-458). IM, NSAA, SAA
66  2021 Population Pharmacokinetic Model of Iohexol in Dogs to Estimate Glomerular Filtration Rate and Optimize Sampling Time. GFR, min
67  2021 Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants. ALK, NSCLC, ROS1
68  2021 Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review. PK, Vd
69  2021 Population Pharmacokinetics and Dosage Optimization of Linezolid in Critically Ill Pediatric Patients. AST, MDR, PD, PICU, PK, PTA
70  2021 Population pharmacokinetics and enterohepatic recirculation of hyzetimibe and its main metabolite in Chinese healthy subjects. EHC
71  2021 Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma. DLBCL, E-R, NHL, R-CHOP, R/R
72  2021 Population pharmacokinetics and exposure-response analyses of varenicline in adolescent smokers. AUC, CAR, E-R
73  2021 Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis. E-R, s.c
74  2021 Population Pharmacokinetics and Exposure-Safety Relationship of Paclitaxel Liposome in Patients With Non-small Cell Lung Cancer. NSCLC, PK
75  2021 Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients. IFIs, MIPD, PK-PD, SCT, TDM, UPLC
76  2021 Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma. ADC, BCMA, CL, cys-mcMMAF, DAR, mAb, RRMM, sBCMA
77  2021 Population Pharmacokinetics of CC-122. ---
78  2021 Population pharmacokinetics of cefazolin in maternal and umbilical cord plasma, and simulated exposure in term neonates. GBS
79  2021 Population Pharmacokinetics of Palbociclib in aReal-World Situation. ---
80  2021 Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data. PEG-ASNase
81  2021 Predictive Performance of Published Tacrolimus Population Pharmacokinetic Models in Thai Kidney Transplant Patients. MAPE, RMSE
82  2021 Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics. LAI, TDM
83  2021 Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients. ANC, ECOG, PK/PD
84  2021 Systematic external evaluation of reported population pharmacokinetic models of vancomycin in Chinese children and adolescents. MAPE, MDPE, NPDE, VPC
85  2021 The significant role of dietary intake of vitamin D in non-menopausal women health. ---
86  2021 Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population Analysis. BDDCS, RUV
87  2021 Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data. MDPE, TDM, UHPLC-HRMS
88  2021 Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model? OAI
89  2020 A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV. CI, GMR
90  2020 A Population Pharmacokinetics Model for Vancomycin Dosage Optimization Based on Serum Cystatin C. CysC, MIC, NONMEM
91  2020 Comparative pharmacokinetic analysis of levonorgestrel-releasing intrauterine systems and levonorgestrel-containing contraceptives with oral or subdermal administration route. COC, IUSs, LNG, POP
92  2020 Determination of propofol in human plasma with C18 pipette-tip based solid-phase extraction followed by liquid chromatography atmospheric-pressure chemical ionization tandem mass spectrometry analysis. SPE
93  2020 Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. ALB, FUMPA, GFR, IMP, MMF, MPAG, RSE, RUVs, SAEM, tMPA, tMPAG, uMPA, uMPAG, VC/F
94  2020 Effects of Surface Characteristics of Polymeric Nanocapsules on the Pharmacokinetics and Efficacy of Antimalarial Quinine. NC, NS, QN
95  2020 Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model. BSA, NONMEM
96  2020 Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer. AAS, ENDO, IM, NM, PM, RSE, TAM, UM
97  2020 Parametric Approaches in Population Pharmacokinetics. ---
98  2020 Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. PK, WAPPS-Hemo
99  2020 Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. cSLE, FFM, SLE, SRI4
100  2020 Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection. AUC, NCA, V/F